Headquartered in Waltham, MA Fiscal year ends December NASDAQ: VRDN viridiantherapeutics.com
Viridian Therapeutics, Inc., based in Waltham, Massachusetts, is a biotechnology firm focused on developing treatments for serious and rare diseases. Its leading projects include VRDN-001, a monoclonal antibody for thyroid eye disease, now in Phase 3 trials, and VRDN-003, a next-generation antibody with potential for the same condition. The company also explores treatments for autoimmune diseases through its preclinical programs VRDN-006 and VRDN-008. Founded in 2010 and originally known as Miragen Therapeutics, it rebranded to Viridian Therapeutics in 2021.
Lumvoa's first quarter on the market brought in $24.7 million in net product revenue, far exceeding expectations against a $4.7 million total revenue consensus. More than 100 patients are already on therapy, pressuring Amgen's Tepezza, and management says the same commercial build supports an elegrobart launch after a BLA submission planned for Q1 2027.
As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company. Studies have shown that insider buys often lead…
IPOs at three biotechs last week tempted insiders to make huge purchases of shares. This effect spilled over into buying at a couple of other biotechs as well.
Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted insiders, as did public offerings.
Viridian Therapeutics, Inc., based in Waltham, Massachusetts, is a biotechnology firm focused on developing treatments for serious and rare diseases.
The Wall Street consensus 12-month price target for VRDN is $39.87.
